Biotricity Inc. (Biotricity) announces its inclusion as a supplier to another major medical system that encompasses 60,000 care providers over 400 hospitals and 400 care centers. This partnership not only expands Biotricity’s market reach but also underscores its commitment to addressing critical gaps in cardiovascular care across the nation.
Biotricity Inc. (Biotricity) announces the launch of a new cardiac monitoring pilot program with a top hospital system. With 90% of U.S. adults at risk of developing cardiovascular disease and a projected shortage of up to 124K physicians in the next 12 years, the demand for Biotricity’s innovative cardiac monitoring solutions has never been more urgent. Integration of Biotricity’s advanced cardiac monitoring solutions into major hospitals will poise the company to play a crucial role in reshaping how cardiovascular health and other chronic diseases are managed.
Biotricity Inc. (Biotricity) today announced the launch of a new cardiac monitoring pilot program with a prominent hospital group encompassing 60 sites spread across multiple states. Biotricity’s cardiac monitoring solution is the only three-channel connected solution in the world. This unique technology results in superior diagnostics, reduced patient risk, and enhanced workflow efficiency, providing improved clinical outcomes while lowering overall healthcare costs.
Biotricity Inc. (Biotricity) today announces the highly anticipated launch of its direct-to-consumer heart health screening program, HeartSecure. HeartSecure represents a monumental leap forward in cardiac monitoring, providing users with unparalleled convenience, affordability, and peace of mind. By increasing access to heart monitoring and empowering individuals to take control of their cardiac health, Biotricity is helping reshape cardiac care.
Biotricity Inc. (Biotricity) has announced the expansion of its cardiac diagnostics portfolio through strategic partnerships with a leading home-based neurology company and a leading home-based sleep apnea diagnostic company. Individuals suffering from sleep or neurological disorders have elevated risks for cardiac issues. These collaborations position Biotricity and its partners as comprehensive providers of holistic screenings, marking a significant advancement in Biotricity’s mission to offer integrated healthcare solutions that address the complex needs of patients with multiple conditions.
Biotricity Inc. (Biotricity) announces high demand for its latest breakthrough device, Biotres Pro. This device is easy to wear, resulting in excellent patient compliance and a higher selling price. Biotres Pro is expected to raise the average subscription price by over 32%.
Biotricity Inc. (Biotricity) announces a groundbreaking cardiac monitoring pilot program with a prestigious hospital group spanning 9 hospitals and 10 clinics. Biotricity will work closely with healthcare professionals to optimize patient interaction protocols and streamline data collection processes. This cardiac monitoring pilot program is poised to showcase the revolutionary impact of Biotricity’s technology suite.
Biotricity Inc. (Biotricity) continues its strategic expansion with the announcement of its latest partnership in neurology to conduct cardiac screenings in patients suffering from neurological issues. There are over 1,000 neurological disorders and over 100 million Americans suffering from at least 1 neurological issue. Alzheimer’s, Parkinsons, and other dementias are just a few such conditions that lead to increased cardiovascular risk. Many of these patients are screened late, leading to an increase in costs and higher patient risk. Biotricity is focused on providing earlier screenings to patients with co-morbidities, reducing costs while improving the quality of care.
Biotricity Inc. (Biotricity) continues its strategic expansion with the announcement of its latest partnership with yet another leading Group Purchasing Organization (GPO). GPOs streamline purchasing processes for medical providers and systems. With this latest partnership, Biotricity’s GPO partners collectively manage the buying needs of 9 out of every 10 hospitals in the U.S. Moreover, they wield immense purchasing power, totaling $264 billion.
Biotricity Inc. (Biotricity) announces the expansion of its Cardiac AI Cloud platform: the company is building a cardiac AI clinical model which distills important information to support clinician in cases that require clinical intervention or review. The company expects to file an FDA clearance for its clinical model by the end of the year.
